BD Q3 Profit Drops 34% to $377M, Misses Estimates; Guides FY EPS $12.62-$12.72
BDX sits 35% above its 52-week low of $127.536.
Summary
BD's Q3 GAAP earnings fell 34% to $377M ($1.37/share) from $574M ($2.00) a year ago, driven by higher costs despite a 5.4% revenue rise to $4.983B, with sales growth aided by higher revenue from surgery tools. Adjusted EPS of $3.23 missed the consensus estimate of $3.31. The company set full-year EPS guidance at $12.62-$12.72, below the prior analyst expectation of $13.05. This is the first earnings miss in recent quarters and follows a strong Q2 where BD raised guidance and completed a $2B buyback. The profit decline and lowered outlook signal margin pressure that will weigh on the stock.
At the time of this announcement, BDX was trading at $172.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $47B. The 52-week trading range was $127.54 to $187.35. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.